menu

What You Need to Know About Strategies for Treating NPDR

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

What You Need to Know About Strategies for Treating NPDR

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?

    Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Rahul N. Khurana, MD

    Partner and Vitreoretinal Surgeon
    Northern California Retina Vitreous Associates
    Mountain View, CA

    Consulting Fees: Aerie, Apellis, Bausch + Lomb, Merck
    Contracted Research: Apellis, Chengdu Kanghong, Graybug, REGENXBIO, Roche

    Faculty:
    Jennifer K. Sun, MD, MPH

    Associate Professor of Ophthalmology
    Harvard Medical School
    Joslin Diabetes Center
    Boston, MA

    Contracted Research: Boehringer Ingelheim, Genentech, Juvenile Diabetes Research Foundation, KalVista Pharmaceuticals
    Consulting Fees: Allergan, Bayer, Current Diabetes Reports, Eleven Biotherapeutics Inc, Kowa Company Ltd, Merck & Co, Novartis, Regeneron, Vindico Medical Education

    Reviewers/Content Planners/Authors:

    • Emily Chew, MD, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Tiarnán Keenan, MD, PhD has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss how the timing of anti-VEGF therapy for diabetic retinopathy (DR) can affect the risk of vision-threatening complications
    • Create individualized management strategies to prevent progression of DR based on pathology and clinical assessment
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, eye health nurses, primary care physicians, nurse practitioners, physician assistants, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?

    Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Rahul N. Khurana, MD

    Partner and Vitreoretinal Surgeon
    Northern California Retina Vitreous Associates
    Mountain View, CA

    Consulting Fees: Aerie, Apellis, Bausch + Lomb, Merck
    Contracted Research: Apellis, Chengdu Kanghong, Graybug, REGENXBIO, Roche

    Faculty:
    Jennifer K. Sun, MD, MPH

    Associate Professor of Ophthalmology
    Harvard Medical School
    Joslin Diabetes Center
    Boston, MA

    Contracted Research: Boehringer Ingelheim, Genentech, Juvenile Diabetes Research Foundation, KalVista Pharmaceuticals
    Consulting Fees: Allergan, Bayer, Current Diabetes Reports, Eleven Biotherapeutics Inc, Kowa Company Ltd, Merck & Co, Novartis, Regeneron, Vindico Medical Education

    Reviewers/Content Planners/Authors:

    • Emily Chew, MD, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Tiarnán Keenan, MD, PhD has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss how the timing of anti-VEGF therapy for diabetic retinopathy (DR) can affect the risk of vision-threatening complications
    • Create individualized management strategies to prevent progression of DR based on pathology and clinical assessment
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, eye health nurses, primary care physicians, nurse practitioners, physician assistants, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule5 Dec 2022